TrialPanorama/Dataset huggingface dataset:
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Antiarrhythmic Trial With Dronedarone in Moderate to Severe CHF Evaluating Morbidity Decrease
Brief Summary: The purpose of this study is to assess the efficacy, tolerability and safety of dronedarone versus placebo in patients with symptomatic congestive heart failure (CHF) and left ventricular dysfunction (LVD) when added to evidence based treatments for CHF.


Options:
A: Arm Label: Dronedarone 400mg bid; Type: EXPERIMENTAL; Interventions: Drug: dronedarone (SR33589) | Arm Label: Amiodarone 600mg/200mg od; Type: ACTIVE_COMPARATOR; Interventions: Drug: amiodarone | Intervention Type: DRUG; Name: dronedarone (SR33589); Assigned to Arm(s): Dronedarone 400mg bid | Intervention Type: DRUG; Name: amiodarone; Assigned to Arm(s): Amiodarone 600mg/200mg od
B: Arm Label: Dronedarone 400mg bid; Type: EXPERIMENTAL; Interventions: Drug: Dronedarone (SR33589) | Arm Label: Placebo; Type: PLACEBO_COMPARATOR; Interventions: Drug: placebo | Intervention Type: DRUG; Name: Dronedarone (SR33589); Assigned to Arm(s): Dronedarone 400mg bid | Intervention Type: DRUG; Name: placebo; Assigned to Arm(s): Placebo
C: Arm Label: Dronedarone 400mg bid; Type: EXPERIMENTAL; Interventions: Drug: Dronedarone (SR33589) | Arm Label: Placebo; Type: EXPERIMENTAL; Interventions: Drug: placebo | Intervention Type: DRUG; Name: Dronedarone (SR33589); Assigned to Arm(s): Dronedarone 400mg bid | Intervention Type: DRUG; Name: placebo; Assigned to Arm(s): Placebo
D: Arm Label: Dronedarone 400mg bid; Type: EXPERIMENTAL; Interventions: Drug: Dronedarone (SR33589) | Arm Label: Placebo; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo | Intervention Type: DRUG; Name: Dronedarone (SR33589); Assigned to Arm(s): Dronedarone 400mg bid | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): Placebo

Answer: D
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Telemedical Interventional Monitoring in Heart Failure (TIM-HF)
Brief Summary: Superiority of additional Remote Patient Monitoring in patients with CHF In comparison to usual care in terms of:

* reduction of mortality rate
* reduction of hospitalizations
* increasement of patients' quality of life


Options:
A: Arm Label: 1; Type: EXPERIMENTAL; Interventions: Device: Remote patient monitoring (Partnership for the Heart) | Arm Label: 2; Type: ACTIVE_COMPARATOR; Interventions: Device: Usual care group | Intervention Type: DEVICE; Name: Remote patient monitoring (Partnership for the Heart); Assigned to Arm(s): 1 | Intervention Type: DEVICE; Name: Usual care group; Assigned to Arm(s): 2
B: Arm Label: Home Monitoring; Type: ACTIVE_COMPARATOR; Interventions: Other: Home Monitoring | Arm Label: In-Office Conventional Follow-up; Type: OTHER; Interventions: Other: In-Office Conventional Follow-up | Intervention Type: OTHER; Name: Home Monitoring; Assigned to Arm(s): Home Monitoring | Intervention Type: OTHER; Name: In-Office Conventional Follow-up; Assigned to Arm(s): In-Office Conventional Follow-up
C: Arm Label: Usual Care; Type: NO_INTERVENTION; Interventions: N/A | Arm Label: Technology Assisted Case Management; Type: EXPERIMENTAL; Interventions: Behavioral: Technology-Assisted Case Management | Intervention Type: BEHAVIORAL; Name: Technology-Assisted Case Management; Assigned to Arm(s): Technology Assisted Case Management
D: Arm Label: Telemedicine; Type: N/A; Interventions: N/A | Arm Label: Telephone; Type: N/A; Interventions: N/A

Answer: A
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Efficacy and Safety of CDP870 400 mg in Combination With Methotrexate Compared to Methotrexate Alone in the Treatment of the Signs and Symptoms of Patients With Rheumatoid Arthritis Who Are Partial Responders to Methotrexate
Brief Summary: The main purpose of the study was to determine the efficacy of CDP870 in treating RA signs/symptoms in patients who were partial responders to MTX. Other purposes were to show additional efficacy without increased toxicity and the immunogenic response to CDP870 during combined CDP870 and MTX therapy.


Options:
A: Arm Label: Placebo; Type: PLACEBO_COMPARATOR; Interventions: Other: Placebo | Arm Label: Cimzia; Type: EXPERIMENTAL; Interventions: Biological: Certolizumab pegol | Intervention Type: OTHER; Name: Placebo; Assigned to Arm(s): Placebo | Intervention Type: BIOLOGICAL; Name: Certolizumab pegol; Assigned to Arm(s): Cimzia
B: Intervention Type: DRUG; Name: CDP870; Assigned to Arm(s): N/A
C: Arm Label: Certolizumab Pegol; Type: EXPERIMENTAL; Interventions: Biological: Certolizumab Pegol | Intervention Type: BIOLOGICAL; Name: Certolizumab Pegol; Assigned to Arm(s): Certolizumab Pegol
D: Arm Label: CDP870 100mg; Type: EXPERIMENTAL; Interventions: Drug: CDP870 100mg | Arm Label: CDP870 200mg; Type: EXPERIMENTAL; Interventions: Drug: CDP870 200mg | Arm Label: CDP870 400mg; Type: EXPERIMENTAL; Interventions: Drug: CDP870 400mg | Arm Label: Placebo; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo of CDP870 | Intervention Type: DRUG; Name: CDP870 400mg; Assigned to Arm(s): CDP870 400mg | Intervention Type: DRUG; Name: CDP870 200mg; Assigned to Arm(s): CDP870 200mg | Intervention Type: DRUG; Name: CDP870 100mg; Assigned to Arm(s): CDP870 100mg | Intervention Type: DRUG; Name: Placebo of CDP870; Assigned to Arm(s): Placebo

Answer: B
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Efficacy and Safety of CDP870 400 mg in Combination With Methotrexate Compared to Methotrexate Alone in the Treatment of the Signs and Symptoms of Patients With Rheumatoid Arthritis Who Are Partial Responders to Methotrexate
Brief Summary: The main purpose of the study was to determine the efficacy of CDP870 in treating RA signs/symptoms in patients who were partial responders to MTX. Other purposes were to show additional efficacy without increased toxicity and the immunogenic response to CDP870 during combined CDP870 and MTX therapy.


Options:
A: Arm Label: Open-Label Active Treatment Enrolled from Phase 2; Type: EXPERIMENTAL; Interventions: Drug: CP-690,550 | Arm Label: Open-Label Active Treatment Enrolled from Phase 3; Type: EXPERIMENTAL; Interventions: Drug: CP-690,550 | Intervention Type: DRUG; Name: CP-690,550; Assigned to Arm(s): Open-Label Active Treatment Enrolled from Phase 2 | Intervention Type: DRUG; Name: CP-690,550; Assigned to Arm(s): Open-Label Active Treatment Enrolled from Phase 3
B: Intervention Type: DRUG; Name: CDP870; Assigned to Arm(s): N/A
C: Arm Label: Active 5mg; Type: EXPERIMENTAL; Interventions: Drug: CP-690,550 | Arm Label: Active 10 mg; Type: EXPERIMENTAL; Interventions: Drug: CP-690,550 | Arm Label: Placebo Sequence 1; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo | Arm Label: Placebo Sequence 2; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo | Intervention Type: DRUG; Name: CP-690,550; Assigned to Arm(s): Active 5mg | Intervention Type: DRUG; Name: CP-690,550; Assigned to Arm(s): Active 10 mg | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): Placebo Sequence 1 | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): Placebo Sequence 2
D: Arm Label: 1; Type: EXPERIMENTAL; Interventions: Drug: etanercept | Intervention Type: DRUG; Name: etanercept; Assigned to Arm(s): 1

Answer: B
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Efficacy and Safety of CDP870 400 mg in Combination With Methotrexate Compared to Methotrexate Alone in the Treatment of the Signs and Symptoms of Patients With Rheumatoid Arthritis Who Are Partial Responders to Methotrexate
Brief Summary: The main purpose of the study was to determine the efficacy of CDP870 in treating RA signs/symptoms in patients who were partial responders to MTX. Other purposes were to show additional efficacy without increased toxicity and the immunogenic response to CDP870 during combined CDP870 and MTX therapy.


Options:
A: Arm Label: Sequence 1; Type: EXPERIMENTAL; Interventions: Drug: CP-690,550 | Arm Label: Sequence 2; Type: EXPERIMENTAL; Interventions: Drug: CP-690,550 | Arm Label: Sequence 3; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo, Drug: CP-690,550 | Arm Label: Sequence 4; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo, Drug: CP-690,550 | Intervention Type: DRUG; Name: CP-690,550; Assigned to Arm(s): Sequence 1 | Intervention Type: DRUG; Name: CP-690,550; Assigned to Arm(s): Sequence 2 | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): Sequence 3 | Intervention Type: DRUG; Name: CP-690,550; Assigned to Arm(s): Sequence 3 | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): Sequence 4 | Intervention Type: DRUG; Name: CP-690,550; Assigned to Arm(s): Sequence 4
B: Intervention Type: DRUG; Name: Certolizumab Pegol; Assigned to Arm(s): N/A
C: Intervention Type: DRUG; Name: CDP870; Assigned to Arm(s): N/A
D: Arm Label: Group 1: Placebo + Methotrexate; Type: PLACEBO_COMPARATOR; Interventions: Drug: Methotrexate, Drug: Placebo injection | Arm Label: Group 2: Golimumab 100 mg + Placebo; Type: EXPERIMENTAL; Interventions: Drug: Golimumab 100 mg, Drug: Placebo capsules | Arm Label: Group 3: Golimumab 50 mg + Methotrexate; Type: EXPERIMENTAL; Interventions: Drug: Golimumab 50 mg, Drug: Methotrexate | Arm Label: Group 4: Golimumab 100 mg + Methotrexate; Type: EXPERIMENTAL; Interventions: Drug: Golimumab 100 mg, Drug: Methotrexate | Intervention Type: DRUG; Name: Golimumab 100 mg; Assigned to Arm(s): Group 2: Golimumab 100 mg + Placebo, Group 4: Golimumab 100 mg + Methotrexate | Intervention Type: DRUG; Name: Golimumab 50 mg; Assigned to Arm(s): Group 3: Golimumab 50 mg + Methotrexate | Intervention Type: DRUG; Name: Methotrexate; Assigned to Arm(s): Group 1: Placebo + Methotrexate, Group 3: Golimumab 50 mg + Methotrexate, Group 4: Golimumab 100 mg + Methotrexate | Intervention Type: DRUG; Name: Placebo injection; Assigned to Arm(s): Group 1: Placebo + Methotrexate | Intervention Type: DRUG; Name: Placebo capsules; Assigned to Arm(s): Group 2: Golimumab 100 mg + Placebo

Answer: C
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Efficacy and Safety of CDP870 400 mg in Combination With Methotrexate Compared to Methotrexate Alone in the Treatment of the Signs and Symptoms of Patients With Rheumatoid Arthritis Who Are Partial Responders to Methotrexate
Brief Summary: The main purpose of the study was to determine the efficacy of CDP870 in treating RA signs/symptoms in patients who were partial responders to MTX. Other purposes were to show additional efficacy without increased toxicity and the immunogenic response to CDP870 during combined CDP870 and MTX therapy.


Options:
A: Arm Label: 1; Type: ACTIVE_COMPARATOR; Interventions: Drug: Etanercept , Methotrexate | Arm Label: 2; Type: ACTIVE_COMPARATOR; Interventions: Drug: Methotrexate; sulfasalazine; hydroxychloroquine;leflunomide | Intervention Type: DRUG; Name: Etanercept , Methotrexate; Assigned to Arm(s): 1 | Intervention Type: DRUG; Name: Methotrexate; sulfasalazine; hydroxychloroquine;leflunomide; Assigned to Arm(s): 2
B: Intervention Type: DRUG; Name: CDP870; Assigned to Arm(s): N/A
C: Arm Label: Adalimumab; Type: EXPERIMENTAL; Interventions: Biological: Adalimumab, Drug: Methotrexate placebo | Arm Label: Adalimumab + methotrexate; Type: EXPERIMENTAL; Interventions: Biological: Adalimumab, Drug: Methotrexate | Arm Label: Methotrexate; Type: EXPERIMENTAL; Interventions: Drug: Methotrexate, Biological: Adalimumab placebo | Intervention Type: BIOLOGICAL; Name: Adalimumab; Assigned to Arm(s): Adalimumab, Adalimumab + methotrexate | Intervention Type: DRUG; Name: Methotrexate; Assigned to Arm(s): Adalimumab + methotrexate, Methotrexate | Intervention Type: BIOLOGICAL; Name: Adalimumab placebo; Assigned to Arm(s): Methotrexate | Intervention Type: DRUG; Name: Methotrexate placebo; Assigned to Arm(s): Adalimumab
D: Intervention Type: DRUG; Name: CDP870; Assigned to Arm(s): N/A

Answer: B
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Efficacy and Safety of CDP870 400 mg in Combination With Methotrexate Compared to Methotrexate Alone in the Treatment of the Signs and Symptoms of Patients With Rheumatoid Arthritis Who Are Partial Responders to Methotrexate
Brief Summary: The main purpose of the study was to determine the efficacy of CDP870 in treating RA signs/symptoms in patients who were partial responders to MTX. Other purposes were to show additional efficacy without increased toxicity and the immunogenic response to CDP870 during combined CDP870 and MTX therapy.


Options:
A: Intervention Type: DRUG; Name: CDP870; Assigned to Arm(s): N/A
B: Arm Label: Open-Label Active Treatment Enrolled from Phase 2; Type: EXPERIMENTAL; Interventions: Drug: CP-690,550 | Arm Label: Open-Label Active Treatment Enrolled from Phase 3; Type: EXPERIMENTAL; Interventions: Drug: CP-690,550 | Intervention Type: DRUG; Name: CP-690,550; Assigned to Arm(s): Open-Label Active Treatment Enrolled from Phase 2 | Intervention Type: DRUG; Name: CP-690,550; Assigned to Arm(s): Open-Label Active Treatment Enrolled from Phase 3
C: Arm Label: 1; Type: ACTIVE_COMPARATOR; Interventions: Drug: methotrexate, Drug: etanercept | Arm Label: 2; Type: ACTIVE_COMPARATOR; Interventions: Drug: methotrexate, Drug: sulfasalazine, Drug: hydroxychloroquine | Arm Label: 3; Type: ACTIVE_COMPARATOR; Interventions: Drug: methotrexate, Drug: etanercept | Arm Label: 4; Type: ACTIVE_COMPARATOR; Interventions: Drug: methotrexate, Drug: sulfasalazine, Drug: hydroxychloroquine | Intervention Type: DRUG; Name: methotrexate; Assigned to Arm(s): 1, 2, 3, 4 | Intervention Type: DRUG; Name: sulfasalazine; Assigned to Arm(s): 2, 4 | Intervention Type: DRUG; Name: hydroxychloroquine; Assigned to Arm(s): 2, 4 | Intervention Type: DRUG; Name: etanercept; Assigned to Arm(s): 1, 3
D: Arm Label: 1; Type: EXPERIMENTAL; Interventions: Drug: tocilizumab [RoActemra/Actemra], Drug: Methotrexate | Arm Label: 2; Type: EXPERIMENTAL; Interventions: Drug: tocilizumab [RoActemra/Actemra], Drug: Methotrexate | Arm Label: 3; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo, Drug: Methotrexate | Intervention Type: DRUG; Name: tocilizumab [RoActemra/Actemra]; Assigned to Arm(s): 1 | Intervention Type: DRUG; Name: tocilizumab [RoActemra/Actemra]; Assigned to Arm(s): 2 | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): 3 | Intervention Type: DRUG; Name: Methotrexate; Assigned to Arm(s): 1, 2, 3

Answer: A
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Continuous Versus Interrupted Abdominal Wall Closure After Emergency Midline Laparotomy: CONTINT - A Randomized Controlled Study
Brief Summary: Patients undergoing primary midline laparotomy for an emergency surgical intervention with a suspected septic focus in the abdominal cavity.


Options:
A: Arm Label: A; Type: ACTIVE_COMPARATOR; Interventions: Procedure: Interrupted sutures | Arm Label: B; Type: EXPERIMENTAL; Interventions: Procedure: Continuous sutures | Intervention Type: PROCEDURE; Name: Interrupted sutures; Assigned to Arm(s): A | Intervention Type: PROCEDURE; Name: Continuous sutures; Assigned to Arm(s): B
B: Arm Label: PDS II; Type: ACTIVE_COMPARATOR; Interventions: Device: PDS II | Arm Label: PDS plus; Type: EXPERIMENTAL; Interventions: Device: PDS plus | Intervention Type: DEVICE; Name: PDS plus; Assigned to Arm(s): PDS plus | Intervention Type: DEVICE; Name: PDS II; Assigned to Arm(s): PDS II
C: Arm Label: Large tissue bites; Type: ACTIVE_COMPARATOR; Interventions: Procedure: Closure of the abdominal wall after midline incisions | Arm Label: small tissue bites; Type: EXPERIMENTAL; Interventions: Procedure: Closure of the abdominal wall after midline incisions | Intervention Type: PROCEDURE; Name: Closure of the abdominal wall after midline incisions; Assigned to Arm(s): Large tissue bites, small tissue bites
D: N/A

Answer: A
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Structured Stroke Management Improves Outcome at 6 Months
Brief Summary: Background/Aim of the study: To further reduce the 6 months stroke morbidity and mortality in a high volume stroke hospital and to compare the results with national and international data.

Methods: 204 consecutive stroke patients are analyzed in a prospective study in a single center teaching institution. The intervention consists of a structured therapeutic chain of 290 collaborating GPs, a standardised acute hospital proceeding overlapping with an early integrated neurovascular rehabilitation within the same institution. Primary endpoints include death and dependence at 6 months, secondary endpoints are the length of hospital stay (LOS) and the quantitative analysis of physical and psychosocial impairments. The data are directly compared with the same endpoints of the Swiss subgroup of the international stroke trial (IST).


Options:
A: Arm Label: TCM integrated group; Type: ACTIVE_COMPARATOR; Interventions: Other: acupuncture, massage and basic TCM treatment | Arm Label: Western Medicine group; Type: ACTIVE_COMPARATOR; Interventions: Other: rehabilitation and WM basic treatment | Intervention Type: OTHER; Name: acupuncture, massage and basic TCM treatment; Assigned to Arm(s): TCM integrated group | Intervention Type: OTHER; Name: rehabilitation and WM basic treatment; Assigned to Arm(s): Western Medicine group
B: Intervention Type: PROCEDURE; Name: structured therapeutic chain of stroke treatment; Assigned to Arm(s): N/A
C: Arm Label: Inpatient hospitalization; Type: ACTIVE_COMPARATOR; Interventions: Other: Traditional inpatient hospitalization | Arm Label: Home hospitalization; Type: EXPERIMENTAL; Interventions: Other: Home hospitalization | Intervention Type: OTHER; Name: Home hospitalization; Assigned to Arm(s): Home hospitalization | Intervention Type: OTHER; Name: Traditional inpatient hospitalization; Assigned to Arm(s): Inpatient hospitalization
D: Arm Label: 1; Type: EXPERIMENTAL; Interventions: Other: Treatment of elderly patients in GHHS | Arm Label: 2; Type: ACTIVE_COMPARATOR; Interventions: Other: Treatment of elderly patients in a GMW | Intervention Type: OTHER; Name: Treatment of elderly patients in a GMW; Assigned to Arm(s): 2 | Intervention Type: OTHER; Name: Treatment of elderly patients in GHHS; Assigned to Arm(s): 1

Answer: B
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Structured Stroke Management Improves Outcome at 6 Months
Brief Summary: Background/Aim of the study: To further reduce the 6 months stroke morbidity and mortality in a high volume stroke hospital and to compare the results with national and international data.

Methods: 204 consecutive stroke patients are analyzed in a prospective study in a single center teaching institution. The intervention consists of a structured therapeutic chain of 290 collaborating GPs, a standardised acute hospital proceeding overlapping with an early integrated neurovascular rehabilitation within the same institution. Primary endpoints include death and dependence at 6 months, secondary endpoints are the length of hospital stay (LOS) and the quantitative analysis of physical and psychosocial impairments. The data are directly compared with the same endpoints of the Swiss subgroup of the international stroke trial (IST).


Options:
A: Arm Label: Pre-intervention group (Control group); Type: N/A; Interventions: N/A | Arm Label: Post-intervention group (Training course group); Type: N/A; Interventions: Other: training of emergency professionals to acute stroke management | Intervention Type: OTHER; Name: training of emergency professionals to acute stroke management; Assigned to Arm(s): Post-intervention group (Training course group)
B: Intervention Type: PROCEDURE; Name: structured therapeutic chain of stroke treatment; Assigned to Arm(s): N/A
C: Arm Label: Intervention; Type: OTHER; Interventions: Other: Implementation of stroke mobility guidelines | Arm Label: Control; Type: NO_INTERVENTION; Interventions: N/A | Intervention Type: OTHER; Name: Implementation of stroke mobility guidelines; Assigned to Arm(s): Intervention
D: Arm Label: TCM integrated group; Type: ACTIVE_COMPARATOR; Interventions: Other: acupuncture, massage and basic TCM treatment | Arm Label: Western Medicine group; Type: ACTIVE_COMPARATOR; Interventions: Other: rehabilitation and WM basic treatment | Intervention Type: OTHER; Name: acupuncture, massage and basic TCM treatment; Assigned to Arm(s): TCM integrated group | Intervention Type: OTHER; Name: rehabilitation and WM basic treatment; Assigned to Arm(s): Western Medicine group

Answer: B
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Structured Stroke Management Improves Outcome at 6 Months
Brief Summary: Background/Aim of the study: To further reduce the 6 months stroke morbidity and mortality in a high volume stroke hospital and to compare the results with national and international data.

Methods: 204 consecutive stroke patients are analyzed in a prospective study in a single center teaching institution. The intervention consists of a structured therapeutic chain of 290 collaborating GPs, a standardised acute hospital proceeding overlapping with an early integrated neurovascular rehabilitation within the same institution. Primary endpoints include death and dependence at 6 months, secondary endpoints are the length of hospital stay (LOS) and the quantitative analysis of physical and psychosocial impairments. The data are directly compared with the same endpoints of the Swiss subgroup of the international stroke trial (IST).


Options:
A: Arm Label: usual care; Type: NO_INTERVENTION; Interventions: N/A | Arm Label: basic intervention; Type: SHAM_COMPARATOR; Interventions: Other: basic intervention | Arm Label: extended intervention; Type: SHAM_COMPARATOR; Interventions: Other: extended intervention | Intervention Type: OTHER; Name: basic intervention; Assigned to Arm(s): basic intervention | Intervention Type: OTHER; Name: extended intervention; Assigned to Arm(s): extended intervention
B: Arm Label: MI + IVR; Type: EXPERIMENTAL; Interventions: Behavioral: MI + IVR | Arm Label: Usual Care; Type: NO_INTERVENTION; Interventions: N/A | Intervention Type: BEHAVIORAL; Name: MI + IVR; Assigned to Arm(s): MI + IVR
C: Arm Label: Usual Care; Type: NO_INTERVENTION; Interventions: N/A | Arm Label: C-TraIn; Type: EXPERIMENTAL; Interventions: Other: Care Transitions Innovation (C-TraIn) | Intervention Type: OTHER; Name: Care Transitions Innovation (C-TraIn); Assigned to Arm(s): C-TraIn
D: Intervention Type: PROCEDURE; Name: structured therapeutic chain of stroke treatment; Assigned to Arm(s): N/A

Answer: D